Strategic Drivers and Operational Performance
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
-
Revenue growth of 8.9% was primarily driven by a 5.7% increase in discharges and a 4% rise in net revenue per discharge, reflecting a strategic shift toward higher-acuity patient populations.
-
Management attributed the pricing strength to increased patient acuity, specifically in categories like stroke, brain injury, and major trauma, which offset declines in lower-acuity joint replacement volumes.
-
The company achieved its lowest level of contract labor since Q4 2020, at 0.9% of total FTEs, marking 16 consecutive quarters of year-over-year reductions in premium labor spend.
-
Strategic positioning in the stroke market was reinforced by updated clinical guidelines recommending inpatient rehabilitation over skilled nursing facilities, supporting the 18% of patient mix currently represented by stroke recovery.
-
Operational efficiency was enhanced through 'career ladder' programs for clinicians, which improved retention and supported the treatment of medically complex patients while maintaining high discharge-to-community rates.
-
The repeal of North Carolina's Certificate of Need law has allowed the company to prioritize 15 new markets for development, with 6 real estate parcels already under contract to address underserved demand.
Growth Strategy and 2027 Outlook
-
The 2026 capacity expansion plan includes opening 2 more hospitals and adding up to 45 beds in the fourth quarter, contributing to a total of 8 new hospitals for the full year.
-
Management expects 2027 performance to be supported by the anniversary of unit closures and the expansion of the Medicare Advantage 'admit-and-appeal' strategy across all hospitals for stroke patients.
-
The 'hub-and-spoke' strategy will utilize new small-format hospitals to penetrate markets with physical expansion constraints, with a goal of reaching at least 6 such openings annually by 2028.
-
The company expects bad debt expense to normalize to its historical range of 2% to 2.5% in Q4 2026 following the resolution of a one-time billing and collection disruption caused by a system conversion.
-
Future capital allocation will prioritize an accelerating pipeline of de novo projects and bed additions, while maintaining a target leverage ratio near 2.0x and continuing share repurchases.
Regulatory and Operational Risk Factors
-
Bad debt expense rose to 2.7% in Q3 due to a temporary billing disruption following a conversion to an Oracle patient billing system, though management expects this to clear by year-end.
-
Adjusted EBITDA guidance was impacted by a $7 million reduction in expected net provider tax contributions for 2026, which is now expected to be $3 million, primarily due to pending CMS approval of the Florida state-directed payment program.
-
The expansion of the Review Choice Demonstration (RCD) to 75 additional hospitals in 2027 introduces administrative risk, as the contractor Palmetto must manage a 10x increase in claim volume.
Q&A Session Insights
Medicare Advantage admit-and-appeal strategy effectiveness
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
-
Management reported an 87% overturn rate on denied claims within the pilot program, with 81% of those overturned before reaching the Administrative Law Judge level.
-
The strategy led to 9.3% total discharge growth in pilot markets, prompting management to expand the program to all hospitals for stroke-related claims.
Small format hospital returns and operational rationale
-
Small format hospitals are expected to achieve a 20% internal rate of return (IRR) by sharing administrative staff with host hospitals to keep labor costs low.
-
Initial delays in the small format pipeline were attributed to navigating new permitting and licensing requirements for the novel design on a state-by-state basis.
Capacity constraints and bed addition prioritization
-
Management identified 58 hospitals running at greater than 90% capacity, with 19 of those sites scheduled for bed additions by the end of 2027.
-
The company is utilizing small format hospitals as a solution for markets where existing facilities face physical limitations that prevent traditional bed expansions.
RCD expansion and administrative burden on Palmetto
-
Management expressed concern regarding Palmetto's ability to process a 100% prepayment claim review for 75 incremental hospitals starting January 1, 2027.
-
Despite administrative hurdles, management is confident that high affirmation rates will allow hospitals to transition to a 5% spot check review after the first six-month cycle.
